Thus, these findings demonstrate that carfilzomib and bortezomib are able to disrupt HER2/ERα cross-talk and to induce cell death in HER2+/ER+ breast cancer cells with aquired resistance to lapatinib. This evidence concerns the gene ERBB2 and breast carcinoma.